Ovarian function, fertility and reproductive lifespan in cancer patients
Authors:
- 28 March 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 13 (3) , 125-136
Abstract
The increasing survival of girls and young women after cancer has led to a rapid growth in research into assessment of ovarian function after treatment. This aim of this review is to discuss normal ovarian function over time, the impact of cancer treatment on ovarian function, the assessment of ovarian reserve after treatment, and pretreatment predictors of ovarian recovery. Ovarian function damage after chemotherapy and radiotherapy will impact on fertility and reproductive lifespan, but with great variability. Age at menopause has implications for the duration of estrogen deficiency, with its own adverse health consequences. This has led to identification of the key treatment and patient factors at the time of treatment, notably age and ovarian reserve that impact on post-treatment ovarian function. However, most studies have used outcome measures such as ongoing menses, or biomarkers such as anti-mullerian hormone (AMH), with few reporting on fertility or age at menopause.Keywords
Funding Information
- Medical Research Council (MR/N022556/1)
This publication has 122 references indexed in Scilit:
- Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancerEuropean Journal of Cancer, 2013
- Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood CancerJAMA, 2013
- Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapyFertility and Sterility, 2013
- Acute ovarian failure underestimates age‐specific reproductive impairment for young women undergoing chemotherapy for cancerCancer, 2011
- Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort studyThe Lancet, 2010
- Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivorsCancer, 2009
- Pregnancy Outcomes in Female Childhood and Adolescent Cancer SurvivorsArchives of Pediatrics & Adolescent Medicine, 2009
- Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patientsJournal of Assisted Reproduction and Genetics, 2009
- A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast CancerCancer Investigation, 2008
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005